Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Synlogic, Inc. is a publicly traded biotechnology company focused on synthetic biology and the development of engineered living medicines designed to treat disease by modifying metabolic pathways within the human body. The company operates within the biotechnology and therapeutics industries, with a historical emphasis on metabolic, immunologic, and rare diseases. Its core technology platform involves genetically engineered probiotic bacteria intended to perform therapeutic functions directly in the body.
The company was founded in 2014 and advanced multiple clinical-stage programs based on its Synthetic Biotic™ platform. However, beginning in 2023, Synlogic announced a significant strategic shift, including the discontinuation of active clinical development programs and a substantial reduction in workforce, as it began exploring strategic alternatives. Based on publicly available filings, the company’s operations have since been substantially reduced, and its activities have primarily centered on evaluating potential asset sales, mergers, or other corporate transactions. Data inconclusive based on available public sources regarding any resumption of active product development.
Business Operations
Historically, Synlogic generated value through the research and development of synthetic biotic drug candidates, rather than commercial product sales. Its primary business activities were organized around its Synthetic Biotic™ Platform, which leveraged engineered strains of probiotic bacteria to sense and respond to disease-related signals. Revenue, when present, was largely derived from collaboration agreements, milestone payments, and research funding rather than product commercialization.
As of the most recent public disclosures, Synlogic no longer maintains active clinical programs or ongoing revenue-generating operations. Domestic operations were historically based in the United States, with research activities conducted internally and through third-party manufacturers and contract research organizations. Data inconclusive based on available public sources regarding any remaining operational partnerships or active subsidiaries.
Strategic Position & Investments
Synlogic’s strategic position has shifted from growth-oriented biotechnology development to capital preservation and strategic review. The company previously pursued growth through internal pipeline advancement and external collaborations, including partnerships with large pharmaceutical companies. Notable historical collaborators included AbbVie Inc., with whom Synlogic explored synthetic biotic approaches for inflammatory diseases.
Following the termination of its development pipeline, Synlogic announced it was exploring strategic alternatives, which may include mergers, asset sales, licensing transactions, or liquidation. No material acquisitions or new investments have been publicly confirmed since this strategic shift. Data inconclusive based on available public sources regarding the outcome of these strategic initiatives or the valuation of remaining intellectual property.
Geographic Footprint
Synlogic is headquartered in Cambridge, Massachusetts, and historically operated primarily within the United States. Its research and corporate functions were concentrated domestically, with limited direct international operations. Clinical trials conducted during its active development phase included sites in North America and Europe, supported through global contract research organizations.
As of its most recent disclosures, the company does not report a significant operational presence outside the United States, nor does it describe ongoing international investments or development activities. Data inconclusive based on available public sources regarding any continued global operational footprint.
Leadership & Governance
Synlogic was founded by leaders in synthetic biology and biotechnology, including James J. Collins, who played a key role in the scientific foundation of the company. Governance and leadership have evolved as the company transitioned from development-stage operations to strategic review.
Key executives and directors disclosed in recent filings include:
- Jean-François Formela – President and Chief Executive Officer
- Lili Liu – Chief Financial Officer
- Alison Lawton – Chair of the Board
- Robert M. Metcalf – Board Member
Leadership communications have emphasized fiduciary responsibility, capital preservation, and the evaluation of strategic alternatives to maximize potential shareholder value, rather than continued independent drug development.